Biocon Intrinsic Value
BIOCON Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹113.38 | ₹90.70 - ₹136.06 | -70.0% | EPS: ₹2.64, Sector P/E: 22x |
| Book Value Method | asset | ₹923.77 | ₹831.39 - ₹1016.15 | +144.4% | Book Value/Share: ₹461.88, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹580.80 | ₹522.72 - ₹638.88 | +53.7% | Revenue/Share: ₹290.40, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹532.05 | ₹478.84 - ₹585.25 | +40.8% | EBITDA: ₹3536.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹919.37 | ₹735.50 - ₹1103.24 | +143.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹113.38 | ₹102.04 - ₹124.72 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹113.38 | ₹102.04 - ₹124.72 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹165.64 | ₹149.08 - ₹182.20 | -56.2% | EPS: ₹2.64, BVPS: ₹461.88 |
Want to compare with current market value? Check BIOCON share price latest .
Valuation Comparison Chart
BIOCON Intrinsic Value Analysis
What is the intrinsic value of BIOCON?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Biocon (BIOCON) is ₹532.05 (median value). With the current market price of ₹377.95, this represents a +40.8% variance from our estimated fair value.
The valuation range spans from ₹113.38 to ₹923.77, indicating ₹113.38 - ₹923.77.
Is BIOCON undervalued or overvalued?
Based on our multi-method analysis, Biocon (BIOCON) appears to be trading below calculated value by approximately 40.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.97 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.12 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 1.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.30x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Biocon
Additional stock information and data for BIOCON
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹4,061 Cr | ₹3,960 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹2,954 Cr | ₹2,453 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,853 Cr | ₹-5,277 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹1,177 Cr | ₹346 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,160 Cr | ₹-666 Cr | Positive Operating Cash Flow | 6/10 |